FindTrial
Sign In

New combination treatment for late fatal complication of measles (SSPE)

Sofosbuvir and Ribavirin in Subacute Sclerosing Panencephalitis - SR-SSPE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028651
Enrollment
10
Registered
2020-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G048- Other encephalitis, myelitis and encephalomyelitis

Interventions

Intervention1: Sofosbuvir and Ribavirin: Sofosbuvir 150-200 mg OD for 3-6 month Ribavirin 200 mg BD for 6 month Control Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Sanjay Sharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children and adult with Subacute Sclerosing Pan Encephalitis

Exclusion criteria

Exclusion criteria: Parents not willing to participate in study

Design outcomes

Primary

MeasureTime frame
Mortality at 18 monthTimepoint: Mortality at 18 month—

Secondary

MeasureTime frame
Improvement or cessation in clinical deteriorationTimepoint: 18 month—

Countries

India

Contacts

Public ContactDr Sanjay Sharma

Ramkrishna Care Medical Sciences Pvt. Ltd. Raipur (CG)

drsanjaysharma12345@gmail.com9893137662

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026